Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,381 to 1,400 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Active Selenium vs Selenium Placebo: Effect of Selenium on Advanced Neoplasia, Analyzed by Active Selenium vs. Selenium Placebo | 269 of 3,326 282 of 3,220 | -0.7 points -2.0 to 0.7 | 6,546 | NCT00706121 S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000 |
| Active Selenium vs Selenium Placebo: Effect of Selenium on Colorectal Adenoma (CRA) Occurrence, Analyzed by Active Selenium vs. Selenium Placebo | 1,136 of 3,326 1,150 of 3,220 | -1.6 points -3.9 to 0.8 | 6,546 | NCT00706121 S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000 |
| Active Selenium vs Selenium Placebo: Effect of Selenium on Occurrences of Multiple (>2) Adenomas | 258 of 3,326 276 of 3,220 | -0.8 points -2.1 to 0.5 | 6,546 | NCT00706121 S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000 |
| Empagliflozin 10 mg vs Placebo: deaths from any cause | 169 of 3,260 178 of 3,262 | -0.3 points -1.4 to 0.8 | 6,522 | NCT04509674 EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) |
| Serelaxin (RLX030) vs Placebo: deaths from any cause | 363 of 3,257 386 of 3,248 | -0.7 points -2.3 to 0.8 | 6,505 | NCT01870778 Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF |
| Serelaxin (RLX030) vs Placebo: serious adverse events | 412 of 3,257 424 of 3,248 | -0.4 points -2.0 to 1.2 | 6,505 | NCT01870778 Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF |
| Ivabradine vs Placebo: Hospitalisation for Worsening Heart Failure | 514 of 3,241 672 of 3,264 | -4.7 points -6.6 to -2.9 | 6,505 | NCT02441218 Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study |
| Ivabradine vs Placebo: Primary Composite Endpoint: First Event Among Cardiovascular Death (Including Death of Unknown Cause) or Hospitalization for Worsening Heart Failure. | 793 of 3,241 937 of 3,264 | -4.2 points -6.4 to -2.1 | 6,505 | NCT02441218 Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study |
| Ivabradine vs Placebo: Unplanned Hospitalisation for CV Reason | 909 of 3,241 1,047 of 3,264 | -4.0 points -6.3 to -1.8 | 6,505 | NCT02441218 Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study |
| Ivabradine vs Placebo: Death From Heart Failure | 113 of 3,241 151 of 3,264 | -1.1 points -2.1 to -0.2 | 6,505 | NCT02441218 Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study |
| Ivabradine vs Placebo: Hospitalisation for Cardiovascular Reason | 977 of 3,241 1,122 of 3,264 | -4.2 points -6.5 to -2.0 | 6,505 | NCT02441218 Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study |
| Ivabradine vs Placebo: Hospitalisation for Any Cause | 1,231 of 3,241 1,356 of 3,264 | -3.6 points -5.9 to -1.2 | 6,505 | NCT02441218 Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study |
| Ivabradine vs Placebo: Secondary Composite Endpoint | 825 of 3,241 979 of 3,264 | -4.5 points -6.7 to -2.4 | 6,505 | NCT02441218 Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study |
| Ivabradine vs Placebo: Cardiovascular Death | 449 of 3,241 491 of 3,264 | -1.2 points -2.9 to 0.5 | 6,505 | NCT02441218 Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study |
| Ivabradine vs Placebo: All-cause Mortality | 503 of 3,241 552 of 3,264 | -1.4 points -3.2 to 0.4 | 6,505 | NCT02441218 Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study |
| Ivabradine vs Placebo: Unplanned Hospitalisation for Any Cause | 1,137 of 3,241 1,264 of 3,264 | -3.6 points -6.0 to -1.3 | 6,505 | NCT02441218 Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study |
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Secondary Safety Outcome: Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeding | 140 of 3,256 100 of 3,248 | 1.2 points 0.3 to 2.1 | 6,504 | NCT02504216 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities |
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Primary Safety Outcome: Number of Participants With TIMI (Thrombolysis in Myocardial Infarction) Major Bleeding | 62 of 3,256 44 of 3,248 | 0.5 points -0.1 to 1.2 | 6,504 | NCT02504216 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities |
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: Secondary Safety Outcome: Number of Participants With BARC (Bleeding Academic Research Consortium) Type 3b and Above Bleeding Events | 93 of 3,256 73 of 3,248 | 0.6 points -0.2 to 1.4 | 6,504 | NCT02504216 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities |
| Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od: deaths from any cause | 327 of 3,256 304 of 3,248 | 0.7 points -0.8 to 2.1 | 6,504 | NCT02504216 Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=70
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00706121-46b5a230",
"title": "Active Selenium vs Selenium Placebo: Effect of Selenium on Advanced Neoplasia, Analyzed by Active Selenium vs. Selenium Placebo",
"summary": "269 of 3326 against 282 of 3220; risk difference -0.7 points, 95% interval -2.0 to 0.7; NCT00706121, S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000",
"record": "/library/comparisons/NCT00706121-46b5a230",
"nct_id": "NCT00706121",
"kind": "outcome",
"participants": 6546,
"risk_difference": {
"value": -0.0066997083023645765,
"lower": -0.02021120543514147,
"upper": 0.006764684362374309
},
"group_1": "269 of 3,326",
"group_2": "282 of 3,220",
"difference": "-0.7 points",
"interval": "-2.0 to 0.7",
"trial_title": "S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000"
},
{
"id": "NCT00706121-beeb9847",
"title": "Active Selenium vs Selenium Placebo: Effect of Selenium on Colorectal Adenoma (CRA) Occurrence, Analyzed by Active Selenium vs. Selenium Placebo",
"summary": "1136 of 3326 against 1150 of 3220; risk difference -1.6 points, 95% interval -3.9 to 0.8; NCT00706121, S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000",
"record": "/library/comparisons/NCT00706121-beeb9847",
"nct_id": "NCT00706121",
"kind": "outcome",
"participants": 6546,
"risk_difference": {
"value": -0.015591444034017687,
"lower": -0.038675895594027905,
"upper": 0.007504165123918018
},
"group_1": "1,136 of 3,326",
"group_2": "1,150 of 3,220",
"difference": "-1.6 points",
"interval": "-3.9 to 0.8",
"trial_title": "S0000D: Effect of Vitamin E and/or Selenium on Colorectal Polyps in Men Enrolled on SELECT Trial SWOG-S0000"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=71",
"request_id": "Xm3VeW4Xt5VMLIdh"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant